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Abstract
Cannabinoid CB1 receptors peripherally modulate energy metabolism. Here, we investi-
gated the role of CB1 receptors in the expression of glucose/pyruvate/tricarboxylic acid
(TCA) metabolism in rat abdominal muscle. Dihydrolipoamide dehydrogenase (DLD), a fla-
voprotein component (E3) of α-ketoacid dehydrogenase complexes with diaphorase activity
in mitochondria, was specifically analyzed. After assessing the effectiveness of the CB1
receptor antagonist AM251 (3 mg kg-1, 14 days) on food intake and body weight, we could
identified seven key enzymes from either glycolytic pathway or TCA cycle—regulated by
both diet and CB1 receptor activity—through comprehensive proteomic approaches involv-
ing two-dimensional electrophoresis and MALDI-TOF/LC-ESI trap mass spectrometry.
These enzymes were glucose 6-phosphate isomerase (GPI), triosephosphate isomerase
(TPI), enolase (Eno3), lactate dehydrogenase (LDHa), glyoxalase-1 (Glo1) and the mito-
chondrial DLD, whose expressions were modified by AM251 in hypercaloric diet-induced
obesity. Specifically, AM251 blocked high-carbohydrate diet (HCD)-induced expression of
GPI, TPI, Eno3 and LDHa, suggesting a down-regulation of glucose/pyruvate/lactate path-
ways under glucose availability. AM251 reversed the HCD-inhibited expression of Glo1 and
DLD in the muscle, and the DLD and CB1 receptor expression in the mitochondrial fraction.
Interestingly, we identified the presence of CB1 receptors at the membrane of striate muscle
mitochondria. DLD over-expression was confirmed in muscle of CB1
-/- mice. AM251
increased the pyruvate dehydrogenase and glutathione reductase activity in C2C12 myo-
tubes, and the diaphorase/oxidative activity in the mitochondria fraction. These results
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indicated an up-regulation of methylglyoxal and TCA cycle activity. Findings suggest that
CB1 receptors in muscle modulate glucose/pyruvate/lactate pathways and mitochondrial
oxidative activity by targeting DLD.
Introduction
The endocannabinoid signaling system (ECS) plays a fundamental role in the onset of obesity
and metabolic disorders, implicating central and peripheral mechanisms predominantly via
the activation of the cannabinoid CB1 receptors [1–4]. Obesity is associated with an increase in
circulating endocannabinoid levels as a consequence of an altered expression of the endocan-
nabinoid-metabolizing enzymes [5,6]. CB1 receptors are mainly expressed in the brain, but
also in many peripheral organs involved in energy metabolism, including striate muscle and
adipose tissue [7–9]. We now know that cannabinoids facilitates energy intake and, perhaps
even more important, enhance energy storage into adipose tissue and reduce energy expendi-
ture in muscle via lipid and glucose metabolism [5,10]. The endocannabinoid anandamide can
modify β-oxidation pathways in the striate muscle, suggesting that CB1 receptor antagonism
could be an important strategy in the regulation of energy expenditure needed to fight obesity
[11]. Importantly, metabolic alterations related to obesity, due to an increased nutrient intake
and/or a decreased fatty acid oxidation, are associated with insulin resistance, with direct
effects on glucose uptake, energy expenditure and mitochondrial function in myocytes [12,13].
As a consequence, deficiency in the skeletal muscle activity produced by insulin resistance and
obesity-linked metabolic dysfunction can be a major risk factor in the development of the so-
called metabolic syndrome, leading to important diseases, such as type 2 diabetes mellitus or
cardiovascular diseases [14,15].
CB1 receptor antagonists (e.g. Rimonabant, AM251) were developed as anti-obesity drugs,
as they are able to antagonize hyperphagia, lead to weight loss and improve cardiometabolic
risk profile and insulin resistance in genetic and dietary animal models of obesity [16–18].
However, SR141716A, which revealed metabolic benefits and body weight reduction in over-
weight and obese human subjects [19,20], induced psychiatric side effects, such as depression
and anxiety, likely derived from a central CB1 receptor inverse agonist activity and leading to
the withdrawal of the drug from the market [21,22]. These adverse effects highlighted the
importance of limiting CB1 receptor antagonism to peripheral organs in order to reduce poten-
tial central risks and enhance peripheral energy balance [23]. However, information is lacking
regarding the impact of CB1 receptors on the peripheral molecular mechanisms of glucose uti-
lization and energy expenditure, which largely depend on muscle metabolism [8].
Here, we identified and evaluated changes in the expression profile of proteins involved in
muscle metabolism, induced by CB1 receptor blockade in the presence or absence of diet-
induced obesity (DIO). We firstly evaluated the most effective dose at which the CB1 receptor
antagonist AM251 reduced food intake. After confirming that the repeated administration (14
days) of AM251 (3 mg kg-1) reduced food/caloric intake and body weight gain in rats fed with
a high-fat diet (HFD) and a high-carbohydrate diet (HCD) for 10 weeks, we then analyzed
both protein and gene expression of key enzymes involved in the regulation of the glucose/
pyruvate/TCA pathways in the abdominal (rectus abdominis) striate muscle. Muscle dihydroli-
poamide dehydrogenase was identified as a relevant mitochondrial enzyme of the TCA cycle
regulated by CB1 receptors. This target was then corroborated in the striate muscle of CB1
-/-
mice, and the mitochondria of striate muscle cell of HCD-fed rats. Finally, results were
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evaluated in conjunction with changes in the diaphorase/oxidative, pyruvate dehydrogenase
and glutathione reductase activity in an in vitromodel, using mytube-differentiated C2C12 cells
and its mitochondria. These results were finally interpreted regarding the subcellular localiza-
tion of the CB1 receptors in the striate muscle and its potential role in the mitochondrial oxida-
tive metabolism.
Materials and Methods
Ethics statements
Experimental procedures with animals were carried out in strict accordance with the recom-
mendations in the European Communities directive 2010/63/EU and Spanish legislation (Real
Decreto 53/2013, BOE 34/11370-11421, 2013) regulating the care and use of laboratory ani-
mals. The protocol was approved by the Ethics Committee for Animal Experiments of the Uni-
versity of Malaga (Permit number: 2014/0003). All efforts were made to minimize animal
suffering and to reduce the number of animals used.
Animals
Ten-weeks-old male Wistar rats (Charles Rivers) and 7-weeks-old male CB1
-/- mice on a
C57BL/6NCrl background [24] were individually housed in standardized conditions of animal
facilities: water ad libitum, 20±2°C room temperature, 40±5% relative humidity and a 12-hours
light/dark cycle (off at 8 pm) with dawn/dusk effect.
Diet-induced obesity (DIO)
Rats were fed ad libitum for 12 weeks with three diets (n = 16): a standard diet (STD; Harlam),
a high-fat diet (HFD, 60% fat diet; D12492, Research Diets Inc), or a high-carbohydrate diet
(HCD, 70% carbohydrate diet; D12450B, Research Diets Inc). The HFD and HCD were used
in order to induce obesity following previous studies [10]. See S1 Text for extended
methodology.
AM251 treatment
A dose-response study was firstly tested to select the most effective treatment for the repeated
study. Rats (n = 8) fed with STD received one intraperitoneal (i.p.) injection of either vehicle
(1 mL kg-1 of 10% Tocrisolve in saline) or CB1 receptor antagonist AM251 [N-(piperidin-
1-yl)-5-(4-iodophenyl)-1-(2,4dichlorophenyl-4-methyl-1H-pyrazole-3-carboxamide] (Tocris;
PubChem, CID:2125) at doses of 0.3, 1, 3 and 10 mg kg-1 of body weight. The cumulative food
intake was measured over a time course of 30, 60, 120 and 240 minutes in rats previously food-
deprived for 24 hours with ad libitum access to water. The minimal dose at which treatment
showed a robust effect on food intake was selected for the repeated treatment experiment.
For repeated treatment, rats (n = 8) fed with STD and HFD for 10 weeks received a daily i.p.
injection of vehicle or AM251 at a dose of 3 mg kg-1 over 14 days. Food intake and body weight
were monitored every two days along feeding and treatment. We generated six experimental
groups (n = 8): STD-vehicle, STD-AM251, HFD-vehicle, HFD-AM251, HCD-vehicle and
HCD-AM251.
Sample collection
Striate muscle from abdominal wall was dissected and frozen at -80°C until mRNA or protein
analyses. Muscle samples were also fixed in 4% formaldehyde for 24 hours and embedded in
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paraffin for histology. Haematoxylin and eosin staining was used for the evaluation of muscle
fiber size, structure and inflammatory state.
Preparation of soluble protein fraction and two-dimensional (2D)
electrophoresis
Abdominal muscle samples were placed on a homogenization buffer supplemented with a pro-
tease inhibitor cocktail (Roche Complete tablets). Then, 100 μl of 2.5 M sucrose was added and
centrifuged at 6,400 g for 5 minutes, and then at 40,000 g for 45 minutes at 4°C. The superna-
tant, correspondent to the cytoplasm fraction of proteins, was measured using the Bradford
assay and frozen at -20°C until the 2D electrophoresis analysis.
Triplicate 2D polyacrylamide gels were performed for each animal (n = 6) to minimize the
effects of intra-assay variation. Isoelectric focusing (IPG) was performed with a Protean IEF
cell (BioRad) using IPG gel strips. Protein extracts (30 μg) were added to a rehydration buffer
(see S1 Text for extended methodology) and added to strips (rehydrated for 18 hours, 50 V and
focused at 40 kV h-1, 20°C). The strips were incubated in two equilibration buffers containing
130 mM dithiothreitol and 135 mM iodoacetamide respectively. The 2-D was performed on
Criterion XT Bis-Tris 12% polyacrylamide gels (80V, 20 minutes and 160V, 70 minutes, 20°C).
The gels were fixed (40% ethanol, 10% acetic acid) for 16 hours, stained using a MS compatible
method (Dodeca™ silver stain kit, Bio-Rad) and analyzed using PDQuest1 Software v7.1 (Bio-
Rad). Normalization of spots was made to compare the optic densities (OD) of the same spot
(amount of protein) on other gels regarding the total density in gel image.
MALDI-TOF and LC-ESI trap MS analyses
Spots with different OD were excised from the gels and trypsinized using the MassPrep Station
(Waters, Micromass) protocol. Extracted peptides (1 μL) were applied to a 96×2 teflon MALDI
target plate (Applied Biosystems), dried to ~50% of the original volume and placed in a α-
cyano-4-hydroxycinnamic acid matrix solution. Gel plugs were also analyzed by nano-HPLC/
ESI ion trap MS, using manual in-gel trypsin digestions of destained spots after reduction and
alkylation with DTT and iodoacetamide, as described above (see S1 Text for extended method-
ology). MALDI-TOF mass spectrometry was performed using an Applied Biosystems Voy-
ager-DE PRO in reflectron mode, as was described previously [25]. LC-ESI MS analysis was
performed using an Agilent 1200 nano-HPLC system equipped with both PepMap100 C-18
trap and analytic columns [26].
RNA isolation and qRT-PCR analysis
Total RNA was extracted from the abdominal muscle (*100 mg) by using the Trizol method, as
previously described [5]. Purified RNA (1 μg) and random hexamers were used to generate first
strand cDNA using transcriptor reverse transcriptase. cDNA was used as a template for quantita-
tive real-time PCR. The relative quantification was normalized to the expression of the housekeep-
ing gene Gapdh and calculated by using the ΔΔCt method. Primers used for the qRT-PCR reaction
were obtained based on TaqMan1Gene Expression Assays (Life Technologies) (Table 1).
Total protein extraction andWestern blot analysis
Protein extracts (75 μg) from mouse abdominal muscle were separated in gradient SDS-PAGE
gels and electroblotted onto nitrocellulose membranes [10]. Specific proteins were detected by
overnight incubation in the corresponding primary antibodies (Table 2). Then, a HRP-conju-
gated anti-rabbit IgG (H+L) or anti-mouse secondary antibodies (Promega) diluted 1:10,000
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was added for 1 h at room temperature. After the enhanced chemiluminiscence detection
(Santa Cruz) in an Autochemi-UVP Bioimaging System, bands were quantified by ImageJ soft-
ware (Rasband, W.S., ImageJ, U.S., NIH, http://imagej.nih.gov/ij, 1997–2012).
Isolation of rat muscle mitochondria for protein (Western blot) analysis
The isolation of muscle mitochondria was realized as described previously [27] with modifica-
tions. Abdominal muscle was collected in isolation medium I (210 mMmannitol, 70 mM
sucrose, 50 mM Trizma and 10 mM EDTA) and digested with trypsin (Gibco) at 0.5 mg g-1 for
30 minutes. Then, the reaction was stopped with a trypsin inhibitor and centrifuged at 1,000 g
for 5 minutes. The supernatant was filtered and centrifuged at 7,000 g for 10 minutes. The
obtained pellet was resuspended in an isolation medium II (225 mMmannitol, 75 mM sucrose,
10 mM Trizma and 0.1 mM EDTA) and centrifuged at 1,000 g for 5 minutes. The resulting
supernatant was centrifuged at 7,000 g for 10 minutes. The obtained pellet (purified mitochon-
drial fraction) was resuspended in 50 μl of isolation medium II. Then, samples were homoge-
nized by sonication and protein concentration was measured using the Bradford method with
BSA as standard.
Western blotting of the mitochondrial protein extracts (30 μl) was performed as was
described above. DLD and CB1 proteins were detected by overnight incubation in the corre-
sponding primary antibodies diluted 1:200 (Table 2).
Table 1. Primer References for TaqMan1Gene Expression Assays (ThermoFisher).
Gene Name Assay ID Amplicon Length
Actb Rn00667869_m1 91
Mm00607939_s1 115
Gapdh Rn01775763_g1 175
Mm99999915_g1 107
Gusb Rn00566655_m1 63
Mm01197698_m1 71
Gpi Rn01475756_m1 85
Mm01962484_u1 84
Tpi1 Rn03021693_g1 100
Mm00833691_g1 197
Eno3 Rn01464911_m1 77
Mm00468267_m1 54
Pkm Rn00583975_m1 76
Mm00834102_gH 182
Dld Rn01648556_m1 68
Mm00432831_m1 82
Ldha Rn00820751_g1 85
Mm01612132_g1 95
Glo1 Rn01429297_g1 84
Mm00844954_s1 154
Cox4i1 Rn00665001_g1 72
Actb, β-actin; Cox4i1, cytochrome c oxidase subunit 4 isoform 1, mitocondrial; Dld, dihydrolipoamide
dehydrogenase; Eno3, β-enolase; Gapdh, glyceraldehyde 3-phosphate dehydrogenase; Glo1, glyoxilase 1;
Gpi, glucose-6-phosphate isomerase; Gusb, β-glucuronidase; Ldha, lactate dehydrogenase; Pkm, pyruvate
kinase; Tpi1, triosephosphate isomerase 1.
doi:10.1371/journal.pone.0145244.t001
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Cell culture and treatment
C2C12 mouse C3H muscle myoblasts (cat. no. 91031101, Sigma-Aldrich) were cultured as pre-
viously described [28]. Proliferating C2C12 cells were propagated in DMEM (ThermoFisher)
supplemented with 5% fetal bovine serum (FBS), 20 mMHEPES, 100 U ml-1 penicillin, 100 μg
ml-1 streptomycin and 1% L-glutamine in a humidified atmosphere of 95% air/5% CO2 at
37°C. Differentiation was achieved upon exposure of proliferating C2C12 cells to a differentia-
tion medium (DM) containing DMEM (25 mM glucose) supplemented with 2% horse serum,
20 mMHEPES, 100 U ml-1 penicillin, 100 μg ml-1 streptomycin and 1% L-glutamine for six
days. To assess C2C12 myotube treatment, cells were first synchronized in fresh DM for 24
hours and then treated with the CB1 receptor agonist ACEA or the CB1 receptor antagonist
AM251 at concentrations of 20, 50, 500, 103 and/or 5103 nM for 2 hours. After treatment, the
cells were first cultured in fresh DM without serum for 2 hours and then incubated in 10 nM
insulin for 10 minutes. Finally, 0.2 mg ml-1 Nitroblue Tetrazolium (NBT) was also added into
the medium for a 3-hours incubation at 37°C in order to detect diaphorase/oxidative reaction
at an optic density of 560 nm (VersaMax Absorbance Microplate Reader, Molecular Devices).
Isolation of C2C12 myotube mitochondria
Mitochondrial extraction from differentiated C2C12 cells was realized as described previously
[29] with modifications. Cells were trypsinised and centrifuged at 1,000 g for 10 minutes. The
pellet was resuspended in a buffer I containing 210 mMmannitol, 70 mM sucrose, 5 mM
HEPES, 1 mM EDTA and 0.5% BSA supplemented with 0.5 mM Tx100. After 15 minutes, per-
meabilization was verified using trypan blue. Samples were centrifuged at 625 g for 5 minutes
and the pellet was resuspended in 10 ml of buffer I and homogenized with 60 gentle strikes in a
glass potter. Membrane disruption was verified under the microscope, and cells were centri-
fuged at 625 g for 5 minutes. The supernatant was centrifuged at 10,000 g for 20 minutes, and
the pellet (purified mitochondrial fraction) was resuspended in 100 μl of a respiration buffer
(75 mMmannitol, 25 mM sucrose, 100 mM KCl, 10 mM Tris-HCl pH 7.4, 50 μM EDTA and
10 mM sodium pyruvate). Protein concentration was measured using the Bradford method
with BSA as standard. Approximately, 1.1 mg of mitochondrial proteins per 106 cells was
recovered.
Diaphorase activity measurement of C2C12 mitochondrial fraction
Mitochondrial samples at a final protein concentration of 0.2 mg ml-1 were incubated in respi-
ration buffer for 10 minutes at 37°C. Samples were first treated with AM251 or ACEA at 20,
50, 500, 103 and 5103 nM for 30 minutes. Then, NBT were added for an overnight incubation
Table 2. Antibodies Used for Protein Detection.
Protein UniProt n° Source Antibody Antibody Dilution Molecular Mass (kDa)
β-actin P68134 Sigma (A5316) 1:2000 42
GPI P06745 Santa Cruz (sc-33777) 1:500 63
TPI P48500 Santa Cruz (sc-22031) 1:1000 30
LDHa P04642 Cell signaling (2012S) 1:1000 37
GLO1 Q6P7Q4 Santa Cruz (sc-50731) 1:1000 24
DLD O08749 Abcam (ab119422) 1:500–1:200 54
CB1 P47746 Abcam (ab23703) 1:200 52
See abbreviations in Table 1.
doi:10.1371/journal.pone.0145244.t002
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at 37°C in order to detect diaphorase/oxidative reaction. Finally, samples were homogenized by
sonication and measured at an optic density of 560 nm.
Measurement of pyruvate dehydrogenase and glutathione reductase
activity in C2C12 myotubes
Myotubes were first synchronized in fresh DM for 24 hours and then treated with ACEA at
1 μM or AM251 at 50 nM for 2 hours. Then, the cells were first cultured in fresh DM without
serum for 2 hours and then incubated in 10 nM insulin for 10 minutes. Finally, the cells were
processed following the protocols described in the respective commercial assay kits in order to
kinetically detect pyruvate dehydrogenase reaction (cat. no. MAK183, Sigma-Aldrich), gluta-
thione reductase reaction (OxiSelectTM GR, cat. no. STA-812, Cell Biolabs, Inc.) and total glu-
tathione content (OxiSelectTM GSSG/GSH, cat. no. STA-312, Cell Biolabs, Inc.) at an optic
density of 450, 405 and 405 nm respectively. One unit of pyruvate dehydrogenase is the
amount of enzyme that generates 1 μmole of NADH per minute at pH 7.5 at 37°C. Pyruvate
dehydrogenase activity was reported as nmole/min/mL relative to control group. Glutathione
content was kinetically determined from the production rate of reduced glutathione (GSH)
from oxidized glutathione (GSSG) for 12 minutes in presence of glutathione reductase and
NADPH. Glutathione reductase activity was reported as mU/min/mL in presence of GSSG and
NADPH.
Electron microscopy
A preembedding silver-intensified immunogold method was used for the localization of CB1
protein as was described [30]. Fifty μm-thick-sections of muscular tissues were first incubated
in primary goat CB1 polyclonal antibodies (2μg ml
-1; CB1-Go-Af450-1; Frontier Science Co.
Ltd) and then in a secondary 1.4 nm gold-labeled rabbit anti-goat IgG (Fab' fragment, 1:100,
Nanoprobes Inc.). Gold particles were silver-intensified with a HQ Silver kit (Nanoprobes
Inc.). Osmicated, plastic-embedded flat in Epon 812. 65 nm ultrathin sections were stained
with uranyl acetate and examined in a Philips EM208S electron microscope.
Statistical analysis
Data were expressed as the mean ± standard error of the mean (s.e.m.) of 6–8 determinations
per experimental group. Statistical analysis were performed using one or two-way ANOVA
with diet (STD, HFD and HCD) and treatment (vehicle and AM251) factors, followed by Bon-
ferroni post-hoc test for multiple comparisons, or one-tailed Student’s t-test with theWelch
correction. A P-value below 0.05 was considered statistically significant.
Results
AM251 effectiveness on food intake and body weight in DIO rats
AM251 administered at 3 and 10 mg kg-1 were the most effective doses on reducing cumulative
food intake over 240 minutes of STD feeding in rats that had been previously food-deprived
for 24 hours feeding (Fig 1A). So, the minimal dose of 3 mg kg-1 was selected for the repeated-
treatment experiment (Fig 1B). After 70 days of HFD and HCD feeding to induce obesity (Fig
1C–1E), AM251 repeatedly administered at 3 mg kg-1 for 14 days produced significant reduc-
tions in cumulative food/caloric intake and body weight gain in a hypercaloric diet-indepen-
dent manner (Fig 1F–1H). Haematoxylin and eosin staining in the abdominal muscle showed
an apparent increase in the amount of adipose tissue located between the muscle fibers of the
rats fed with HFD and HCD (Fig 1I–1K). However, the extension of adipose tissue located
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between the muscle fibers seemed to be reduced after the repeated administration of AM251
(Fig 1L–1N).
Protein identification and characterization in muscle of DIO rats treated
with AM251
Through comprehensive proteomic approaches involving 2D electrophoresis in the rat muscle
of the six experimental groups (STD-vehicle, STD-AM251, HFD-vehicle, HFD-AM251, HCD-
vehicle and HCD-AM251), we selected 7 spots from up to 300 spots analyzed in each 2D gel,
whose average of optic densities (protein content) significantly changed when the experimental
groups were compared (Fig 2A). Each spot represented a single protein showing specific elec-
trochemical properties and molecular weight. MALDI-TOF and LC-ESI MS analyses identified
the same protein hits for the 7 spots: Mascot score, number of peptides, peptide coverage,
molecular weight and isoelectric point, among other parameters, which are highly associated to
the characteristics and the identity of 7 known proteins (Table 3). The 7 proteins identified in
the abdominal muscle were glucose-6-phosphate isomerase (GPI), triosephosphate isomerase
(TPI), beta-beta muscle specific enolase or enolase-3 (Eno3), pyruvate kinase isozyme M1
(PKM1), lactate dehydrogenase A-chain (LDHa), glyoxalase-1 (Glo1), and dihydrolipoamide
dehydrogenase (DLD). These 7 proteins are key regulatory enzymes of the glucose, pyruvate
and lactate metabolism as well as branched-chain amino acids of the tricarboxylic acid (Krebs)
cycle in the striate muscle (Fig 2B–2E).
AM251 regulates the protein expressions of glucose/pyruvate-
metabolizing enzymes in the abdominal muscle of HCD-fed rats
The expression of most proteins identified in muscle was mainly affected by the HCD and the
AM251 treatment (Fig 3). Two-way ANOVA showed a diet effect on the protein expressions of
GPI, TPI, LDHa and Glo1 (GPI/LDHa/Glo1: F1,30>13.88, P<0.001; TPI: F1,30 = 9.83, P<0.01).
A treatment effect on the expressions of all proteins identified was observed (GPI/LDHa/Glo1:
F2,30>22.28, P<0.0001; Eno3/PKM1: F2,30>5.43, P<0.01; TPI: F2,30 = 5.26, P = 0.011). Interac-
tions between diet and treatment were detected for the protein expressions of GPI, TPI, Eno3,
LDHa and Glo1 (GPI/TPI/LDHa/Glo1: F2,30>13.15, P<0.0001; Eno3: F2,30 = 5.59, P<0.01),
indicating that the repeated AM251 administration differentially modified their protein
expression in a diet-dependent manner.
Regarding Bonferroni test (Fig 3), we observed an increased GPI and Eno3 expressions in
HFD-fed rats as well as a higher significance of the increased GPI, TPI, Eno3 and LDHa
expressions in HCD-fed rats (//P<0.05/0.01/0.001) (Fig 3A–3C and 3E). Increased GPI,
TPI and LDHa expressions were also observed in HCD-fed rats compared with HFD ones
(###P<0.001) (Fig 3A, 3B and 3E). Thus, these glucose/pyruvate metabolism enzymes were up-
regulated as a consequence of a hypercaloric carbohydrate diet. In contrast, we detected a
decreased Glo1 expression in HFD-fed rats as well PKM1 and Glo1 in HCD-fed rats
(/P<0.01/0.001) (Fig 3D and 3F). Additionally, decreased PKM1 expression was also
detected in HCD-fed rats compared with HFD ones (#P<0.05) (Fig 3D). Thus, methylglyoxal
pathway key enzymes were down-regulated after a hypercaloric carbohydrate diet.
Fig 1. AM251 effectiveness on food intake and body weight in DIO rats.Dose-response of AM251 (0.3, 1, 3, 10 mg kg-1) in cumulative food intake (A)
and experimental design (B) for cumulative food/caloric intake and body weight gain (C-H) during STD, HFD and HCD feeding for 84 days and repeated
AM251 administration (3 mg kg-1) for 14 days. Bonferroni’s test (n = 8): *P<0.05, **P<0.01, ***P<0.001 vs. STD; #P<0.05, ###P<0.001 vs. HFD; $P<0.05,
$ $ $P<0.001 vs. HFD-vehicle; &&P<0.01, &&&P<0.001 vs. HCD-vehicle. Haematoxylin-eosin staining in the abdominal muscle of the rats fed with STD, HFD
and HCD for 84 days and repeatedly treated with AM251 (3 mg kg-1) for 14 days (I-N).
doi:10.1371/journal.pone.0145244.g001
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Fig 2. Protein identification and characterization in muscle of DIO rats treated with AM251. Seven proteins in the abdominal muscle of STD, HFD and
HCD-fed rats treated with AM251 were identified by using 2-dimensional (2D) electrophoresis and MALDI-TOF/LC-ESI trap mass spectrometry. A) A
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AM251 decreased the GPI and Glo1 expressions in STD-fed rats (P<0.05) (Fig 3A and
3F). AM251 also decreased the GPI, TPI, Eno3 and LHDa expressions specifically in HCD-fed
rats ($/$ $ $P<0.05/0.001) (Fig 3A–3C and 3E). Thus, the expressions of these glucose/
pyruvate metabolism enzymes were specifically blocked after AM251 treatment in a highly-car-
bohydrate context. In contrast, AM251 increased the Glo1 expression in HFD (##P<0.01) and
HCD ($ $ $P<0.001) (Fig 3F).
AM251 regulates the gene expressions of glucose/pyruvate-
metabolizing enzymes in the abdominal muscle of HCD-fed rats
Two-way ANOVA only showed a diet effect on the Gpi and Tpi expressions (F1,38>5.12,
P<0.027) (Fig 4). A treatment effect on the Tpi, Eno3, Pkm and Glo1 expressions were also
observed (Tpi/Pkm/Glo1: F2,37>3.69, P<0.034; Eno3: F2,39 = 33.02, P<0.0001). Interaction was
only detected for the Ldha expression (F2,39 = 3.44, P = 0.041), indicating that AM251 treat-
ment differentially modified its gene expression of in a diet-dependent manner.
Regarding Bonferroni test (Fig 4), we observed an increased Tpi and Eno3 expressions in
HFD-fed rats as well as Gpi, Tpi, Eno3 and Ldha in HCD-fed rats (/P<0.05/0.001) (Fig 4A–
4C and 4E). AM251 only decreased the Gpi, Tpi and Ldha expressions in HCD-fed rats
($P<0.05) (Fig 4A, 4B and 4E).
The expression of the metabolic enzymes in the abdominal muscle of
CB1
-/- mice was altered
To assess the results obtained in the AM251-treated DIO rats, the muscles of CB1
-/- mice were
also analyzed by qRT-PCR andWestern immunoblotting (Fig 5). CB1
-/- mice showed a
decreased gene expression of Tpi1 and Ldha (P<0.05) (Fig 5A), which were confirmed regard-
ing their protein expression (P<0.05) (Fig 5B and 5C). We also observed an increased gene
expression of Glo1 (P<0.05) (Fig 5A) and a decreased protein expression of GPI in CB1
-/-
mice (P<0.05) (Fig 5B).
representative 2D polyacrylamide gel showing the selected spots.B-D) Scheme of the glucose and pyruvate pathways and Krebs cycle showing the step
reaction of the seven enzymes identified. E) Fatty acid metabolism. Dihydrolipoamide dehydrogenase (DLD) is an E3 component with dehydrogenase/
diaphorase activity of the mitochondrial pyruvate1/α-ketoglutarate2/branched-chain α-ketoacid3 dehydrogenase complexes.
doi:10.1371/journal.pone.0145244.g002
Table 3. Proteins Identified using 2D Electrophoresis and MALDI-TOF/LC-ESI MS Analyses.
ID No. Score Pept COV MW/pI Protein Identiﬁed
7603 Q6P6V0 957 15 33 63.0/7.4 Glucose-6-phosphate isomerase (GPI)
5204 P48500 1169 13 64 27.3/6.5 Triosephosphate isomerase (TPI)
3502 P15429 114 6 16 47.0/7.1 Beta-enolase (Eno3 or MSE)
5701 P11980 76 6 11 58.3/6.6 Pyruvate kinase isozyme M1 (PKM1)
8801 P04642 319 12 37 36.7/8.4 Lactate dehydrogenase A chain (LDHa)
0101 Q6P7Q4 50 3 10 21.0/5.1 Glyoxalase 1 (Glo1)
4601 Q6P6R2 129 4 11 54.6/8.0 Dihydrolipoamide dehydrogenase (DLD)
ID, Identiﬁcation number of the spot; Score, Mascot score from the MOWSE algorithm for peptide mass ﬁngerprinting; Pept, number of peptides
indentiﬁed; COV, peptide coverage over the protein; MW, molecular weight; pI, isoelectric point. For each hit, the higher Mascot score obtained from the
two MS approaches was selected.
doi:10.1371/journal.pone.0145244.t003
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AM251 regulates the expression of DLD and Cox4i1 in the abdominal
muscle of HCD-fed rats
We analyzed the muscle expression of DLD enzyme, an E3 component of the mitochondrial
pyruvate/α-ketoglutarate dehydrogenase complexes, which regulates TCA cycle activity and
cellular respiration (Fig 6). Two-way ANOVA showed a treatment effect on the DLD protein
expression (F2,30 = 8.47, P = 0.0012). Interaction in Dld expression (F2,37 = 3.24, P = 0.05) indi-
cated that AM251 differentially modified its expression in a diet-dependent manner. Regarding
Bonferroni test, both HFD and HCD decreased the protein and gene expressions of DLD
(//P<0.05/0.01/0.001) (Fig 6A and 6B). Decreased protein expression of DLD in HCD-
fed rats compared with HFD ones (#P<0.05) was also observed. Increased protein and gene
expressions of DLD was specifically detected in the muscle of AM251-treated HCD-fed rats
($P<0.05) (Fig 6A and 6B) and confirmed in CB1
-/- mice (/P<0.05/0.001) (Fig 6D and 6E).
We also analyzed the gene expression of Cox4i1, a mitochondrial respiratory chain enzyme
(Fig 6C). Two-way ANOVA showed a diet effect on Cox4i1 expression (F1,40 = 15.66,
P = 0.0003). The presence of interaction (F1,40 = 3.8, P = 0.03) indicated that AM251
Fig 3. AM251 regulates the protein expressions of glucose/pyruvate-metabolizing enzymes. AM251 effects on the protein expressions of GPI, TPI,
Eno3, PKM1, LDHa and Glo1 in the abdominal muscle of STD, HFD and HCD-fed rats (A-F). Representative 2D polyacrylamide gels showing the intensity of
the identified spots (G). Bonferroni’s test (n = 6): *P<0.05, **P<0.01, ***P<0.001 vs. STD-vehicle; #P<0.05, ##P<0.01, ###P<0.001 vs. HFD-vehicle; $P<0.05,
$ $ $P<0.001 vs. HCD-vehicle.
doi:10.1371/journal.pone.0145244.g003
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differentially modified the Cox4i1 expression in a diet-dependent manner. Thus, HFD induced
a decreased Cox4i1 expression when it was compared with STD and HCD (/#P<0.05). How-
ever, AM251 increased the Cox4i1 expression in both HFD and HCD-fed rats (#/$P<0.05)
(Fig 6C).
Localization of the CB1 receptors in the rodent striate muscle
Little is known concerning the expression and subcellular distribution of CB1 receptors in mus-
cles. Therefore, we set to analyze CB1 receptor expression in the muscle abdominalis using
immunogold electron microscopy (Fig 7). Interestingly, images showed immunogold particles
labeling CB1 receptors in the outer membrane of the mitochondria of the rat and mouse striate
muscle (Fig 7A–7D), whereas no electrodense particles were found in the striate muscle of
CB1
-/- mouse (Fig 7E and 7F). Thus, the above-described effects of the CB1 receptor antagonist
AM251 on glucose/pyruvate/lactate pathways might be partially mediated by direct modula-
tion of mitochondrial functions.
AM251 increases the protein expression of CB1 receptor and DLD in the
muscle mitochondria of HCD-fed rats
To assess the above affirmation, the presence and protein expression of the CB1 receptor and
DLD in the mitochondrial fraction of muscle of AM251-treated DIO rats were evaluated by
Western immunoblotting (Fig 7G–7I). Two-way ANOVA showed diet and treatment
effects, and interaction between factors on CB1 receptor expression in the muscle mitochon-
dria (F1,12 = 8.20, P = 0.014; F1,12 = 9.22, P = 0.010; F1,12 = 12.18, P = 0.004 respectively). No sig-
nificant effect on the DLD protein expression was observed. Regarding Bonferroni test, both
HFD and HCD decreased the protein expression of CB1 receptor and DLD (
/P<0.05/0.01)
Fig 4. AM251 regulates the gene expressions of glucose/pyruvate-metabolizing enzymes. AM251 effects on the gene expressions ofGpi, Tpi1, Eno3,
Pkm, Ldha andGlo1 in the abdominal muscle of STD, HFD and HCD-fed rats. Bonferroni’s test (n = 8): *P<0.05, ***P<0.001 vs. STD-vehicle; $P<0.05 vs.
HCD-vehicle.
doi:10.1371/journal.pone.0145244.g004
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(Fig 7G and 7H). However, AM251 specifically increased the protein expression of CB1 recep-
tor and DLD in the muscle mitochondria of HCD-fed rats ($P<0.05) (Fig 7G and 7H).
AM251 increased diaphorase/oxidative activity in the C2C12 cell
mitochondria
Given that the diaphorase/oxidative activity of the DLD enzymes plays a critical role through
redox reactions in the TCA cycle, we aimed at clarifying the biological significance of the
increased DLD expression in the muscle mitochondria after CB1 receptor pharmacological
blockade. To this end, we first investigated the effect of the CB1 receptor blockade (AM251)
and activation (ACEA) on the diaphorase activity of C2C12 myotubes in culture (Fig 8A–8G).
Fig 5. Expression of the metabolic enzymes in the abdominal muscle ofCB1-/- mice.Gene (A) and protein (B) expressions of GPI, TPI, Eno3, PKM1,
LDHa and Glo1 in the abdominal muscle of wild-type andCB1
-/- mice. C)Representative immunoblots. Student’s t test (n = 6): *P<0.05 vs. WT.
doi:10.1371/journal.pone.0145244.g005
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Under conditions of basal oxidative state, insulin induced an increase of diaphorase/oxidative
activity (P<0.05) (Fig 8A and 8B). AM251 produced an enhancement of this effect when it
was compared with either control group (/P<0.01/0.001) or insulin group (&/&&&P<0.05/
0.001) (Fig 8A and 8C–8E). Moreover, AM251 at a dose of 50 nM showed a maximal increase
of the diaphorase/oxidative activity (Fig 8A and 8E). However, no specific effect or an opposed
effect on the diaphorase/oxidative activity were observed when the C2C12 myotubes were
treated with increased concentrations of ACEA (Fig 8B, 8F and 8G).
After checking the protein expression of CB1 receptor and DLD in the mitochondrial frac-
tion of C2C12 myotubes (Fig 8H), we then investigated the effect of the CB1 receptor blockade
(AM251) and activation (ACEA) on the diaphorase activity of C2C12 myotube mitochondria in
vitro (Fig 8I). AM251 produced a dose-response increase of diaphorase/oxidative activity when
it was compared with the control group (/P<0.05/0.01). However, no effect was observed
when the mitochondrial fractions of C2C12 myotubes were incubated with ACEA (Fig 8I).
AM251 increased pyruvate dihydrogenase and glutathione reductase
activity in the C2C12 myotubes
To further assess the increased diaphorase activity and the putative mitochondrial ROS pro-
duction in the C2C12 myotubes after CB1 receptor pharmacological blockade, we evaluated the
Fig 6. AM251 regulates the expression of DLD and Cox4i1. AM251 effects on the protein and gene expressions of DLD (A,B) and the gene expression of
Cox4i1 (C) in the abdominal muscle of STD, HFD and HCD-fed rats. Representative 2D polyacrylamide gels showing the intensity of the identified spots for
DLD (D). Bonferroni’s test (n = 6–8): *P<0.05, **P<0.01, ***P<0.001 vs. STD-vehicle; #P<0.05 vs. HFD-vehicle; $P<0.05 vs. HCD-vehicle. Gene (D) and
protein (E) expressions of DLD in the abdominal muscle of wild-type andCB1
-/-mice. Representative immunoblots (F). Student’s t test (n = 6): *P<0.05,
***P<0.001 vs. WT.
doi:10.1371/journal.pone.0145244.g006
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Fig 7. CB1 receptors in the striate muscle and AM251 effects on the mitochondrial CB1 receptor and DLD. Electron immunogold detection of CB1
receptors (arrows) on the mitochondrial (mt) membrane of striate muscle cells in rats (A,B), and wild-type (C,D) andCB1
-/- (E,F) mice. Scale bars: 0.5μm.
AM251 effects on the protein expression of CB1 receptor (G) and DLD (H) in the purified mitochondrial fraction of the abdominal muscle of STD, HFD and
HCD-fed rats. Representative immunoblots (I). Bonferroni’s test (n = 8): *P<0.05, **P<0.01 vs. STD-vehicle; $P<0.05 vs. HCD-vehicle.
doi:10.1371/journal.pone.0145244.g007
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Fig 8. AM251 increased diaphorase/oxidative, pyruvate dehydrogenase and glutathione reductase activity. AM251 and ACEA effects on the
diaphorase/oxidative activity in C2C12 myotubes in culture (A,B), and in the C2C12 mitochondrial fraction in vitro (I). AM251 and Representative images of
Anti-Obesity Role of CB1 Receptor in Muscle Metabolism
PLOSONE | DOI:10.1371/journal.pone.0145244 December 15, 2015 17 / 23
pyruvate dehydrogenase and glutathione reductase activity (Fig 8J–8L). Under conditions of
basal oxidative state, insulin induced an increase of glutathione reductase activity (P<0.05)
(Fig 8L). AM251 at 50 nM induced an enhancement of pyruvate dehydrogenase and glutathi-
one reductase activity, and showed a lower GSSG-to-GSH rate (as a consequence of a low
GSSG content), when it was compared with either control group (/P<0.01/0.001) or insu-
lin group (&P<0.05) (Fig 8J–8L). In contrast, ACEA at 1μM produced an increased GSSG-to-
GSH rate (elevated GSSG content) and a decreased activity of glutathione reductase, when it
was compared with either control group (P<0.01) or insulin group (&/&&&P<0.05/0.001)
(Fig 8K and 8L).
Discussion
Here we demonstrated that the expression of relevant metabolic enzymes involved in the regu-
lation of glucose (GPI, TPI), pyruvate (Eno3, PKM1, LDHa), glyoxalase-1 (Glo1) and TCA and
amino acid catabolism (DLD) pathways in the abdominal rat muscle was altered in a hyperca-
loric diet-dependent manner. The significant alteration in the protein expression of GPI, TPI,
Eno3, LDHa, Glo1 and DLD showed a complete normalization after the systemic administra-
tion of the CB1 receptor antagonist AM251 at the effective dose of 3 mg kg
-1 for 14 days in the
obese rats specifically fed with a HCD. AM251 effects on muscle metabolism should be associ-
ated with a reduction in food/caloric intake and body weight gain [5,6,10]. Firstly, we observed
that AM251 amended the HCD-induced increase of the protein expression of GPI, TPI, Eno3
and LDHa, and alleviated the HCD-induced decrease of the protein expression of Glo1. Sec-
ondly, we described that both CB1 receptor antagonism and deletion (CB1
-/-) specifically
displayed similar changes in the expression of the muscle DLD, an E3 component of the mito-
chondrial pyruvate/α-ketoglutarate/branched-chain keto acid (BCKDC) dehydrogenase
complexes with dehydrogenase/diaphorase activity (Fig 9A). Thus, AM251 counteracted the
HCD-induced decrease in the protein and gene expression of DLD in rat muscle, an effect that
was confirmed after the protein analysis of DLD in the muscle mitochondrial fraction. Thirdly,
we identified the presence of CB1 receptors at the outer membrane of striate muscle mitochon-
dria, as was previously described in brain, suggesting a direct endocannabinoid regulation of
mitochondrial activity in the muscle [31]. Moreover, we showed that AM251 reversed the
HCD-induced decrease in the protein expression of CB1 receptor in the muscle mitochondrial
fraction. Finally, regarding these results and the relevance of the redox activity of DLD in the
TCA cycle, we evaluated the influence of the CB1 receptor blockade (AM251) and activation
(ACEA) in the dehydrogenase and diaphorase/oxidative activity that can be detected in vitro in
a cell model of differentiated C2C12 myotubes. We observed that AM251, but not ACEA,
induced an enhancement of the diaphorase activity detected in the mitochondria of myotube-
differentiated C2C12 cells, which was in accordance with the increased activity of pyruvate
dehydrogenase and glutathione reductase in the C2C12 myotubes (Fig 9).
These results agree with the fact that CB1 receptor antagonism has a direct effect on periph-
eral energy utilization [4]. Although the ECS has been shown to be expressed in the skeletal
muscle [5,7], little information about the effects of CB1 receptor blockade on muscle oxidative
pathways and energy expenditure have been reported [8]. The present study demonstrated the
ability of the CB1 receptor antagonist AM251 to restore the expression levels of specific
enzymes, such as GPI, TPI, Eno3 and LDHa, related with glucose and pyruvate metabolism in
differentiated C2C12 cells showing NBT staining (C-G). Representative immunoblots of CB1 receptor and DLD from the total and mitochondrial protein
fractions of C2C12 myotubes (H). ACEA effects on the pyruvate dehydrogenase, glutathione content and glutathione reductase activity in C2C12 myotubes in
culture (J-L). ANOVA (n = 8): *P<0.05, **P<0.01, ***P<0.001 vs. control C2C12 (white bar);
&P<0.05, &&&P<0.001 vs. insulin C2C12 (black bar).
doi:10.1371/journal.pone.0145244.g008
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an insulin-highly sensitive tissue (striate muscle), which have been specifically increased after
the chronic administration of a high-carbohydrate diet. We interpreted that the up-regulation
of the glucose/pyruvate metabolism enzymes can be a response to catalyze the excess of glucose
availability. Consequently, the down-regulation of these metabolic enzymes by AM251 under a
highly-carbohydrate context can be contributing to the improved glycaemia and insulin resis-
tance described in previous studies [19,32]. Both mitochondrial respiratory activity and bio-
genesis were decreased in the skeletal muscle of obese/diabetic animal models and humans
[33,34]. Thus, CB1 receptor activation impaired mitochondrial biogenesis in peripheral tissues,
whereas the blockade showed opposite effects [35,36]. Because the cannabinoid receptor block-
ade has been implicated in the regulation of mitochondrial function, we focused in the mito-
chondrial candidate identified by the proteomic approach: the DLD, a relevant TCA cycle
enzyme with NADH-related diaphorase activity coupled to mitochondrial respiration. We
demonstrated that both HFD and HCD decreased the mitochondrial DLD expression in mus-
cle. However, the abdominal muscle of HFD-fed rats, but not HCD-fed rats, showed a
decreased expression of the mitochondrial respiratory chain gene Cox4i1. These results can be
interpreted as the mitochondrial bioenergetics is particularly impaired after an excess of fatty
acid availability by the diet, but seems less relevant in a highly-carbohydrate context [34]. In
contrast, AM251 increased the Cox4i1 gene expression in both HFD and HCD-fed rats, but it
only increased the mitochondrial DLD expression in HCD-fed rats. In this case, the net effect
of AM251-induced blockade of CB1 receptor in muscle might be an activation of mitochon-
drial respiration and, as a consequence, a potential increase in energy expenditure under a
Fig 9. Scheme showing the enzymatic reactions that catalyze the pyruvate dehydrogenase complex, including pyruvate dehydrogenase activity
and diaphorase activity of DLD (A) as well as the glutathione reductase/peroxidase activity (B). NBT staining is proportional to O- production from
redox activity.
doi:10.1371/journal.pone.0145244.g009
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highly-carbohydrate context. Nonetheless, these potential effects on mitochondrial respiration
need to be confirmed in future experiments.
DLD and Cox41i up-regulation by AM251 must be coupled to the increased diaphorase/oxi-
dative, pyruvate dehydrogenase and gluthatione reductase activity specifically detected in
C2C12 myotubes under an elevated availability of glucose (25 mM) in the differentiation culture
medium. We propose that a higher production of NADH by the pyruvate dehydroganase activ-
ity and the increased diaphorase/oxidative activity, probably partaken by DLD, can be a
response to the increased acidification of the mitochondrial matrix [37]. In our study, a higher
level of protons in the mitochondrial matrix can be deduced from the up-regulation of the
mitochondrial respiratory chain gene Cox41i. It has been described that the skeletal insulin
resistance and the onset of type 2 diabetes produced an impairment of pyruvate dehydrogenase
activity, which is, in turn, potently activated by exercise [38]. Our results suggest that the CB1
receptor antagonist AM251 could also counteract this deleterious effect on pyruvate dehydro-
genase activity. We detected an increased activity of glutathione reductase after AM251 treat-
ment. Because this enzyme is a key cellular antioxidant, our results suggest that the CB1
receptor inhibition can boost the breakdown of dangerous reactive molecules such as hydrogen
peroxide [39,40].
Until recently, the effects of cannabinoids on oxidative metabolism were interpreted either
as an indirect activation of plasma membrane CB1 receptors, or as unspecific alterations of the
mitochondrial membranes [41]. However, novelty studies [31,42] challenged this concept as
CB1 receptors are also present in the mouse neuronal mitochondria and can directly modulate
neuronal energy metabolism. For instance, different CB1 receptor agonists (THC, WIN55,212–
2, HU210) couldn’t decrease respiration rates of purified brain mitochondria from CB1
-/- mice
[31]. We demonstrated that CB1 receptors are also present in the muscle mitochondria by
using immunogold electron microscopy. As a consequence, in agreement with previous studies,
we suggest that CB1 receptor might directly regulate mitochondrial metabolism in muscle by
targeting the pyruvate dehydrogenase activity and the diaphorase/oxidative activity, probably
partaken by DLD [43,44]. The confirmation of this hypothesis will be addressed in future
studies.
In conclusion, we evidenced that the pharmacological blockade of CB1 receptors by AM251
at an effective dose of 3 mg kg-1 preferably modulates the muscle expression of selected glu-
cose/pyruvate metabolic enzymes and the mitochondrial TCA cycle (and amino acid oxida-
tion) enzyme DLD, which can promote an increased diaphorase/oxidative activity in response
to an excess of carbohydrate availability. These results coupled to the presence of CB1 receptors
in the muscle mitochondria demand further studies in order to support a new mechanism of
action on energy expenditure through the muscle mitochondrial metabolism.
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